• Season 2

Episode 14: Cell Therapy Pioneers

How do we make CAR T cell therapy more safe and effective? How can we target solid tumors? In this episode we hear from two cell therapy pioneers: Dr Michael Jensen & Dr Michel Sadelain.... Read More
  • Season 2

Episode 13: Immunotherapy or Bust

This episode comes from ASCO 2016 in Chicago, the annual meeting of the American Society of Clinical Oncology. In it, you’ll hear experts such as Dr Johanna Bendell, Dr Jérôme Galon, and Dr Stephen Liu talk... Read More
  • Season 2

Episode 12: Of Mice and Men

At the 2016 annual meeting of the American Association for Cancer Research (AACR) one topic that attracted a lot of attention and debate was the use of mouse models to guide cancer immunotherapy drug development... Read More
  • Season 2

Episode 11: Cancer Immunity Cycle

We’re excited to start season 2 of the Novel Targets Podcast with an episode on the Cancer Immunity Cycle! While in New Orleans for the 2016 annual meeting of the American Association for Cancer Research... Read More
  • Season 1

Episode 10: New Horizons in Hematology

At the 2015 annual meeting of the American Society of Hematology (ASH) we heard about some of the latest data in blood cancers such as AML, CLL and Multiple Myeloma. Ian W. Flinn MD, PhD... Read More
  • Season 1

Episode 9: Targeting the Microbiome

In this episode we’re looking at how to make therapies that target our immune system more effective. Could it be as simple as changing the composition of the bacteria in the gut, the intestinal microbiome... Read More
  • Season 1

Episode 8: The Pioneers – Part 1

A pioneer is someone who helps develop something new and prepares the way for others to follow. We want to harness our immune system to fight and cure cancer. In this episode you’ll hear from... Read More
  • Season 1

Episode 7: European Cancer Congress

This episode is from the European Cancer Congress that took place in Vienna, Austria from September 25-29, 2015. You will hear leading experts talk about the latest cancer immunotherapy data. Professor Tom Powles (Barts, London)... Read More
  • Season 1

Episode 6: Stepping on the Gas

This episode features excerpts from an interview with Dr Holbrook Kohrt who was leading the way in researching the potential of immune agonists targeting 4-1BB (CD137). It is with great sadness that we must report that since... Read More
  • Season 1

Episode 5: Titans of Adoptive Cell Therapy

This episode features interviews with two Titans in the field of adoptive cell therapy: Dr Carl June from the University of Pennsylvania (UPenn) and Dr Steven Rosenberg from the National Cancer Institute (NCI). Adoptive cellular... Read More
  • Season 1

Episode 4: Non-Inflamed Tumor Show

Checkpoint inhibitors do not work well in cancers where there is no underlying immune response. One example of such a non-inflamed tumor is prostate cancer. So a key question is how do we convert a... Read More
  • Season 1

Episode 3: ASCO Lung Cancer Show

Lung cancer is the No 1 cause of cancer related death in the United States. Which is why the whole of this episode is devoted to the latest lung cancer data presented at the 2015... Read More
  • Season 1

Episode 2: The Immune Biomarker Show

We’ve heard about the promise of cancer immunotherapy and in particular checkpoint inhibitors, but not everyone responds. It’s typically around 25-30% in most cancers. So how do we identify those patients that are likely to... Read More
Novel Targets Podcast © 2015-16